Fig. 7.

Effects of the GRPR antagonist RC-3095 and NPRA antagonist A71915 on intradermal SLIGRL-induced c-Fos activation. Each antagonist was intrathecally administered 10 minutes prior to SLIGRL. Expression of c-Fos protein in cervical dorsal horn was evaluated 2 hours after intradermal administration of SLIGRL by immunohistochemistry. Representative micrograph (A) and mean number of c-Fos⁺ cells (C) in each group are shown. (B) Higher magnification of bordered square in vehicle/SLIGRL indicates c-Fos overlaps with DAPI. Scale bars, 100 μm (A) and 20 μm (B). Each value represents mean ± S.E.M. (n = 5). ***P < 0.001 versus vehicle control, ^##P<0.01 versus vehicle/SLIGRL. ns, Not significant versus vehicle/SLIGRL.